Mobius Therapeutics™ To Host Livestream Discussion on July 11th

Arsham Sheybani, MD of Washington University and Lori Pacheco of Orbis to discuss Mitosol®

12:00 noon EDT - https://www.facebook.com/ophthalmicprofessional

ST. LOUIS, July 7, 2022 /PRNewswire/ -- Mobius Therapeutics™, LLC

, a St. Louis-based perioperative ophthalmic pharmaceutical company, will host a live stream discussion between Arsham Sheybani, MD of Washington University and Lori Pacheco, RN, CRNO of Orbis International. The stream may be accessed July 11 at 12:00 noon EDT at https://www.facebook.com/ophthalmicprofessional

Preview

来源: PRNewswire

Mitosol (mitomycin for solution) 0.2 mg/vial, Kit for Ophthalmic Use

Preview

来源: PRNewswire

Mitosol (mitomycin for solution) Kit for Ophthalmic Use (PRNewsfoto/Mobius Therapeutics, LLC)

Preview

来源: PRNewswire

Preview

来源: PRNewswire

Mobius Therapeutics™ To Host Livestream on July 11th Arsham Sheybani MD and Lori Pacheco RN to discuss Mitosol®

Tweet this

"Mitosol® customers approach intraoperative use of antimetabolites from very different, yet closely allied positions," said Ed Timm, CEO of Mobius Therapeutics. "While their needs are distinct, resolution is found with the use of Mitosol®."

Mitosol® is the only FDA approved formulation of mitomycin-c bearing an ophthalmic indication. With room temperature storage and shelf life of up to 24 months, Mitosol® offers unique flexibility to providers, as its "shelf-ready" status permits on demand utility.

"Dr. Sheybani and Lori are renowned experts in their fields, offering impactful, real-world voices," continued Timm. "Having earned their advocacy and endorsement is a privilege. They tell us that Mitosol®, delivers value at every level: to the patient, the provider, and the American healthcare system."

About Mobius Therapeutics, LLC:

Mobius Therapeutics is a commercial stage venture focused on sterile perioperative ophthalmic pharmaceuticals. Mitosol® (mitomycin for solution) 0.2 mg/vial, Kit for Ophthalmic Use, is the only formulation of mitomycin-c bearing an ophthalmic indication. Mobius maintains additional perioperative formulations in commercialization, as well as an active product pipeline. Please see full prescribing information at https://mitosol.com/mitosol-package-insert/.

CONTACT:

Ed Timm

Mobius Therapeutics, LLC

314-615-6932

[email protected]

SOURCE Mobius Therapeutics, LLC

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。